Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

PolyNovo Limited

Healthcare US CALZF

0.6786USD
0.00(0%)

Last update at 2026-06-19T20:00:00Z

Day Range

0.600.60
LowHigh

52 Week Range

0.551.20
LowHigh

Fundamentals

  • Previous Close 0.68
  • Market Cap414.51M
  • Volume19538
  • P/E Ratio60.00
  • Dividend Yield-%
  • EBITDA6.65M
  • Revenue TTM139.49M
  • Revenue Per Share TTM0.20
  • Gross Profit TTM 121.95M
  • Diluted EPS TTM0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax 7.52M 1.71M -4.93310M -1.15092M -4.55040M
Minority interest - - - - -
Net income 13.21M 5.26M -4.92454M -1.19253M -4.60503M
Selling general administrative 94.12M 75.26M 53.20M 28.58M 24.05M
Selling and marketing expenses 4.45M 3.29M - 1.26M 0.80M
Gross profit 122.05M 97.71M 60.81M 39.24M 27.60M
Reconciled depreciation 2.70M 2.19M 2.04M 1.59M 0.92M
Ebit 7.75M 1.85M -5.08856M 0.54M -4.32777M
Ebitda 10.45M 4.05M -2.70952M 2.13M -3.40709M
Depreciation and amortization 2.70M 2.19M - 1.59M 0.92M
Non operating income net other - - - - -
Operating income 4.48M 1.16M -6.18502M 0.54M -4.32777M
Other operating expenses 122.76M 102.03M - 41.70M 32.31M
Interest expense 0.24M 0.72M 0.19M 0.32M 0.22M
Tax provision -5.69500M -3.55000M -0.00856M 0.04M 0.05M
Interest income 0.49M 1.53M 0.87M 0.00067M 0.00110M
Net interest income -0.39500M 0.81M 0.16M -0.31470M -0.32030M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -5.69500M -3.55000M -0.00856M 0.04M 0.05M
Total revenue 127.24M 103.19M 65.24M 41.44M 29.16M
Total operating expenses 117.56M 96.55M - 39.49M 30.75M
Cost of revenue 5.20M 5.48M 4.43M 2.20M 1.56M
Total other income expense net 3.04M 0.55M 1.10M -0.57957M -1.08261M
Discontinued operations - - - - -
Net income from continuing ops 13.21M 5.26M -4.92454M -1.19253M -4.60503M
Net income applicable to common shares - - -4.92454M -1.19253M -4.60503M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 127.41M 108.72M 92.62M 34.97M 38.34M
Intangible assets 0.66M 0.91M 1.16M 1.40M 1.65M
Earning assets - - - - -
Other current assets 4.64M 3.64M 0.31M 0.15M 0.15M
Total liab 44.15M 36.60M 27.24M 17.26M 15.99M
Total stockholder equity 83.26M 72.12M 65.38M 17.72M 22.35M
Deferred long term liab - - 0.18M 0.33M 0.48M
Other current liab 18.25M 13.91M 3.28M 1.00M 3.96M
Common stock 191.76M 191.60M 191.59M 139.43M 139.25M
Capital stock 191.76M 191.60M 191.59M 139.43M 139.25M
Retained earnings -102.90300M -116.11700M -121.37831M -116.45377M -115.26124M
Other liab - - 0.42M 0.29M 0.22M
Good will - - - - -
Other assets - -0.44700M 0.74M 0.63M 0.62M
Cash 33.53M 45.91M 46.85M 6.10M 7.69M
Cash and equivalents - - - - -
Total current liabilities 27.88M 23.25M 12.67M 7.76M 8.65M
Current deferred revenue 0.28M 0.21M - - -
Net debt -16.40000M -30.52700M - 4.89M 2.31M
Short term debt 2.41M 2.54M - 1.79M 2.88M
Short long term debt 1.50M 1.89M 1.40M 1.33M 2.53M
Short long term debt total 17.14M 15.38M - 10.99M 10.00M
Other stockholder equity - -0.00000M -4.82986M -5.26164M -1.63722M
Property plant equipment - - 23.37M 16.75M 19.82M
Total current assets 77.10M 79.30M 67.35M 16.19M 16.24M
Long term investments 0.66M 0.57M 0.56M 0.30M 0.14M
Net tangible assets - - 64.23M 16.31M 20.70M
Short term investments 0.05M 0.05M 0.05M 0.05M 0.05M
Net receivables 24.39M 20.72M 13.72M 6.09M 5.67M
Long term debt 2.22M 0.74M 1.79M 2.80M 5.06M
Inventory 14.49M 8.97M 4.53M 2.54M 1.96M
Accounts payable 6.94M 6.39M 2.74M 4.97M 1.81M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -5.59300M -3.36000M - -5.26164M -1.63722M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.04M 0.18M 0.33M 0.48M
Deferred long term asset charges - - - - -
Non current assets total 50.31M 29.43M 25.27M 18.78M 22.10M
Capital lease obligations 13.42M 12.75M 12.86M 6.86M 2.41M
Long term debt total - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -13.21600M -1.49000M -0.84877M 5.86M -3.56723M
Change to liabilities - - 4.17M -0.14233M 2.85M
Total cashflows from investing activities -13.21600M -1.49000M -0.84877M 5.86M -3.56723M
Net borrowings -1.47700M -2.65500M -3.98661M -5.56831M -0.25037M
Total cash from financing activities -2.39100M -3.17000M 48.06M -5.38831M -0.07037M
Change to operating activities - - 0.10M 0.65M 0.04M
Net income 13.21M 5.26M -4.92454M -1.19253M -4.60503M
Change in cash -12.37200M -0.94000M 40.74M -1.58636M -3.95915M
Begin period cash flow 45.91M 46.85M 6.10M 7.69M 11.65M
End period cash flow 33.53M 45.91M 46.85M 6.10M 7.69M
Total cash from operating activities 3.15M 3.68M -6.61253M -2.05703M -0.25022M
Issuance of capital stock - - 52.05M 0.18M 0.18M
Depreciation - 2.74M 2.28M 1.80M 1.12M
Other cashflows from investing activities 0.71M 1.41M 0.68M 0.00040M 0.00148M
Dividends paid - - - - -
Change to inventory - -4.49300M -1.99499M -0.57546M -0.74279M
Change to account receivables - -6.79000M -7.42715M -0.27607M -2.36737M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.91400M -0.51500M - 1.53M 6.89M
Change to netincome - - 1.18M -2.32075M 3.46M
Capital expenditures 13.93M 2.90M 1.53M 0.49M 3.57M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - -9.90800M - - -
Stock based compensation - 1.54M - - -
Other non cash items 3.15M 5.59M - - -
Free cash flow -10.78300M 0.79M -8.14076M -0.49193M -3.56872M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CALZF
PolyNovo Limited		 - -% 0.68 60.00 34.72 2.97 8.57 5.00 100.50
ABT
Abbott Laboratories		 -0.58 0.66% 87.83 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 -3.11 1.01% 304.69 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.07 0.09% 79.27 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.96 2.12% 44.33 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

PolyNovo Limited

320 Lorimer Street, Port Melbourne, VIC, Australia, 3207

Key Executives

Name Title Year Born
Mr. Jan-Marcel Gielen C.A. CFO & Company Sec. NA
Dr. David McQuillan Ph.D. Chief Technical & Scientific Officer NA
Mr. Swami Raote BPHARM, M.B.A. CEO & Director NA
Mr. Ahmed Hassan Director of Operations NA
Ms. Teena Chadha APAC Marketing & Distributor Mang. NA
Ms. Monica Benyk HR Mang. NA
Dr. Tim Moore Principal Scientist NA
Mr. Edward Graubart Sr. VP of Sales & Marketing (Americas) NA
Mr. Jan-Marcel Gielen C.A. CFO & Company Secretary NA
Mr. Bruce Peatey Chief Executive Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.